Bank of Nova Scotia’s NovoCure NVCR Stock Holding History

Bank of Nova Scotia’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-54,700	Closed	-$1.19M	–	924
2018 Q1	$1.19M	Buy	+54,700	New	+$1.18M	0.01%	696

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Bank of Nova Scotia's NVCR Position: Q2 2018 in Review

Bank of Nova Scotia sold out of NovoCure (NVCR) in Q2 2018, closing a stake of 54,700 shares — an estimated $1.19M sold.

Bank of Nova Scotia first reported a position in NVCR in Q1 2018 and held it in 1 quarter. The position peaked at $1.19M in Q1 2018. 161 funds tracked by Wall St. Rank hold NVCR as of Q2 2018.

Bank of Nova Scotia reported no remaining NovoCure position as of Q2 2018 after selling out during the quarter.
Bank of Nova Scotia sold 54,700 NovoCure shares in Q2 2018, an estimated $1.19M.
Bank of Nova Scotia first reported a position in NovoCure in Q1 2018 and held it in 1 quarter.
Bank of Nova Scotia's NovoCure position peaked at $1.19M in Q1 2018.
161 funds tracked by Wall St. Rank held NovoCure as of Q2 2018.

Based on Bank of Nova Scotia's 13F filing for Q2 2018, filed 14 Aug 2018.